Healthcare & Life Sciences

Standard Textile Incontinence Pad Patterned Surface

USPTO granted Design Patent USD1122441S1 to Standard Textile Co., Inc. for an incontinence pad with patterned surface design. The patent has 1 claim under application number 29877572 filed June 8, 2023. Competitors in the incontinence or hygiene product market should review this design patent for potential ornamental design overlap.

Window Handcrank Manipulator Design Patent USD1122478S1

USPTO granted design patent USD1122478S1 for a Window Handcrank Manipulator invented by Robert Fritz. The patent was issued April 14, 2026, with Application No. 29929345 filed February 21, 2024. The design patent contains 1 claim and covers a mechanical device design used for operating window cranks.

Talus Implant Design USD1122446S1, RESTOR3D

USPTO granted Design Patent USD1122446S1 to RESTOR3D, INC. for a Talus Implant design. The patent, with CPC classifications covering foot/ankle implants (A61F 2/42, A61F 2/66), was filed on May 10, 2023 under Application No. 29875805 and contains 1 design claim.

Rural Health FQHC Requirements, Certification, Services

CMS Medicare Learning Network published MLN006397, a booklet covering Federally Qualified Health Center (FQHC) requirements, certification standards, covered services, payment methodologies, and cost reporting obligations. The publication serves as an educational resource for current and prospective FQHCs.

Therapy Efficacy Method via Tissue Analysis, Arion Diagnostics

USPTO granted Patent US12599349B2 to Arion Diagnostics, Inc. covering a method for determining therapeutic agent efficacy through non-invasive biological tissue characterization. The method involves measuring molecular structure of tissue at two time points and observing changes to determine efficacy. The patent includes 27 claims and covers therapeutic applications across multiple CPC classifications including oncology, immunology, and neurological disorders.

US12599625B2 - Nitrous Oxide Oxygen Inhalation Therapy for ARDS

The USPTO granted Patent US12599625B2 to Penland Foundation on April 14, 2026, covering nitrous oxide and oxygen inhalation therapy for treating ARDS and conditions caused by elevated cytokine levels. The patent, invented by Roland M. Williams, contains 22 claims classified under A61K 33/00 and A61P 11/16. The treatment method involves administering nitrous oxide and oxygen by inhalation before, during, and/or after ARDS occurs to address acute cytokine system activation from infections, injuries, or other conditions.

US12599617B2 Methods of Treating Head and Neck Cancers with Hemp Extract Containing CBD

The USPTO granted Patent US12599617B2 to Dove Innovation Pty Limited covering methods of treating head and neck cancers using compositions containing hemp-derived CBD. The patent, with 17 claims, specifically covers mucosal formulations of cannabis extract for cancer treatment. Inventors include Alexandra M. Capano, Pradeep Singh Tanwar, and Alex Nance.

Method of Obtaining Pharmaceutical Agent Inhibiting HeLa Cervical Cancer Cells

USPTO granted Patent US12599626B2 to LLC 'Laboratory of Innovative Technologies' on April 14, 2026. The patent covers a method for producing a pharmaceutical agent for inhibiting proliferation of HeLa cervical cancer cells using metal powder obtained via electric wire explosion of low-carbon steel. The invention involves exploding wire with specific energy of 7-18 KJ/g in carbon monoxide, followed by passivation, mixing with RPMI-1640 nutrient medium, and phase separation to produce the therapeutic agent.

Tricyclic KRAS Inhibitor Patent - Incyte Corporation

The USPTO granted Patent US12600717B2 to Incyte Corporation on April 14, 2026 for tricyclic compounds as inhibitors of KRAS activity. The patent contains 34 claims covering Formula I compounds useful in treating diseases associated with KRAS activity, including cancer. Filing date was July 13, 2022, under application number 17812310.

Salt Inducible Kinase Inhibitors Patent Granted to General Hospital Corporation

USPTO granted patent US12600719B2 to General Hospital Corporation covering salt inducible kinase (SIK) inhibitor compounds and pharmaceutical compositions. Inventors Marc Nathan Wein and William J. Greenlee filed the application on August 5, 2021. The patent contains 20 claims under CPC classification C07D 471/04.

Vanderbilt Cyclopropylpiperidine M4 Antagonists - US12600726B2

The USPTO granted Patent No. US12600726B2 to Vanderbilt University on April 14, 2026, covering cyclopropylpiperidine compounds useful as antagonists of muscarinic acetylcholine receptor M4 (mAChR M4). The patent includes 15 claims and covers methods of making the compounds, pharmaceutical compositions, and methods of treating disorders using the compounds. Vanderbilt University receives enforceable IP rights for this therapeutic compound class.

NURIX BTK Degrading Compounds, 36 Claims, Apr 14

The USPTO granted Patent US12600732B2 to NURIX THERAPEUTICS, INC. on April 14, 2026. The patent covers 36 claims for bifunctional compounds that degrade BTK via the ubiquitin proteolytic pathway, along with pharmaceutical compositions and methods of treatment for various diseases, conditions, or disorders.

Nanjing University of Chinese Medicine - US12600724B2 Indole Alkaloid Compound and Preparation Method

The USPTO granted Patent US12600724B2 to Nanjing University of Chinese Medicine for an indole alkaloid compound represented by formula (I), including its preparation method and pharmaceutical salts. The compound has demonstrated therapeutic effects in animal studies, including promoting axon growth in peripheral sensory neurons, improving nerve conduction velocity in diabetic rats, accelerating foot ulcer wound healing, reducing pulmonary fibrosis, and protecting lung tissues. The patent contains 13 claims covering the compound, formulations, and methods of treatment for diabetic complications.

Evotec Heterocyclic Drug Patent, Apr 14

Evotec Heterocyclic Drug Patent, Apr 14

Tetracyclic DGK Inhibitor Compounds for Cancer Treatment

USPTO granted Patent US12600722B2 to Incyte Corporation for tetracyclic compounds that modulate diacylglycerol kinase (DGK) activity, useful in treating cancer including solid tumors. The patent names Joshua Hummel, Shicheng Shi, and Xiaozhao Wang as inventors and contains 63 claims.

Interleukin-17 Inhibitors Patent - Novartis AG

The USPTO granted patent US12600728B2 to NOVARTIS AG covering novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds as Interleukin-17 (IL-17) inhibitors. The patent also protects processes for preparing these compounds, pharmaceutical compositions, and medicaments for treating diseases and disorders mediated by IL-17.

ONO Pharmaceutical ABHD6 Antagonist Patent US12600730B2

USPTO granted Patent US12600730B2 to ONO Pharmaceutical Co., Ltd. on April 14, 2026, covering substituted cyclopenta[c]pyrrole compounds as ABHD6 antagonists for pharmaceutical use. The patent includes 18 claims for compounds useful in preventing or treating diseases associated with ABHD6 enzyme inhibition. The application was filed on April 8, 2024.

Washington University Patent for Toxoplasma Gondii Treatment Compounds

The USPTO granted Patent US12600727B2 to Washington University on April 14, 2026, covering compounds and methods for treating infections caused by Toxoplasma gondii and related parasites. The patent includes 18 claims and lists inventors L. David Sibley, Joshua Radke, Eamon Comer, Marshall Morningstar, and Bruno Melillo. This grant provides Washington University with exclusive intellectual property rights for the developed antiparasitic compounds and their pharmaceutical applications.

ELI LILLY AND COMPANY - KRAS Inhibitor Compounds for Cancer Treatment Patent Grant

The USPTO granted Patent US12600733B2 to Eli Lilly and Company on April 14, 2026, covering KRAS inhibitor compounds for treating cancer. The patent includes 30 claims for compounds of specified formula and their use in pharmaceutical compositions. Filing date was September 30, 2025.

Interoperability Standards for Prior Authorization APIs for Medicare Advantage, Medicaid, CHIP, and QHP Issuers

CMS proposes requiring Medicare Advantage organizations, Medicaid FFS programs, CHIP FFS programs, Medicaid managed care plans, CHIP managed care entities, and QHP issuers on FFEs to implement electronic prior authorization APIs for drugs. The rule would extend existing interoperability requirements to cover drug prior authorizations, adopt HL7 FHIR standards as HIPAA-covered transaction standards, require API endpoint reporting to CMS, and add a definition of failure to report for civil monetary penalty purposes.

FDA Center for Tobacco Products Complaint Submission

The FDA Center for Tobacco Products received a complaint document under docket FDA-2026-H-3868. The comment period has closed and no documents are available for public viewing. The nature and content of the complaint are not accessible through the regulatory filing system.

Acknowledgment Letter to Mom3nts Production

FDA's Center for Devices and Radiological Health (CDRH), Division of Manufacturers and Communication (DMB), issued an acknowledgment letter to Mom3nts Production. The letter confirms receipt of a submission filed under docket FDA-2025-V-3791. No documents are available for public viewing on Regulations.gov; the letter content is contained in an attachment.

FDA Center for Tobacco Products Files Complaint - April 2026

The FDA Center for Tobacco Products (CTP) filed a complaint on April 14, 2026, initiating a formal enforcement action against tobacco product manufacturers. The complaint was submitted to regulations.gov under docket FDA-2026-H-3832. This filing represents FDA's regulatory enforcement mechanism for addressing violations of tobacco product standards under the Family Smoking Prevention and Tobacco Control Act.

LAA Occlusion Devices, Systems, and Methods Patent US12599386B2

USPTO granted patent US12599386B2 to Laminar, Inc. covering devices, systems, and methods for occluding the left atrial appendage (LAA) using implants that expand against cavity walls and twist to gather tissue, which can then be secured with fasteners. The patent, granted April 14, 2026, contains 5 claims and was filed August 28, 2020.

Emergency Protocol Receptacle for Puncture Wounds - Patent US12599387B2

USPTO granted Patent US12599387B2 to Jesse Radford for an emergency protocol receptacle designed for puncture wounds. The invention utilizes an endothermic chemical reaction between vinegar and baking soda to inflate a balloon, facilitating faster blood coagulation in puncture-type wounds. The patent covers a balloon, powder capsule, and depressible top cap configuration.

Zimmer Patent for Bone Graft Delivery Systems Granted

The USPTO granted Patent US12599388B2 to Zimmer, Inc. covering bone graft delivery devices and methods. The invention includes a cannula and cartridge system for compacting and delivering bone material through fluid communication to an implantation site. The patent names six inventors and contains 15 claims.

Bard Vascular Occlusion Device Patent US12599384B2 Granted

USPTO granted US Patent No. 12,599,384 (B2) to Bard Peripheral Vascular, Inc. on April 14, 2026, for a vascular occlusion device featuring an adjustable body with a pair of lobes and an adjustment assembly. The device allows modification of lobe distance through an elongated member and receiving member mechanism. The patent includes 20 claims and covers methods of use for vascular occlusion procedures.

Electrode Balloon Catheter and High-Voltage Generation Processing Device Patent Grant

USPTO granted Patent US12599391B2 to Shanghai Microport Rotapace Medtech Co., Ltd. for an electrode balloon catheter and high-voltage generation processing device. The invention includes a balloon, inner catheter, and shock wave generation component with a flexible circuit layer enabling reduced passage size. The patent contains 15 claims and covers electrode arrangements positioned within the balloon connected via flexible circuitry.

Medical Instrument with Consistent Smoothness of Action - US12599392B2

The USPTO granted Patent US12599392B2 to Aesculap AG for a medical instrument featuring improved pivot mechanism design with bearing portions and shoulder elements that ensure consistent sliding action. The patent, filed October 18, 2021, contains 19 claims covering surgical instruments with enhanced operational smoothness. Aesculap AG and its inventors Sven Barthelmes, Holger Loesdau, Christian Stark, and Markus Knecht hold the rights to this technology.

US12599389B2 - Multi-Sided Cutting Instrument for Mobilizing Small Foot Bones

USPTO granted patent US12599389B2 to Treace Medical Concepts, Inc. covering a multi-sided orthopedic cutting instrument with multiple cutting surfaces designed for mobilizing and realigning small bones in the foot. The invention includes a handle and cutting head with lead and side cutting surfaces arranged to control soft tissue cutting while limiting inadvertent deep penetration. The patent contains 31 claims and is classified under CPC codes A61B 17/1682, A61B 17/32, A61B 17/1659, and A61B 17/1604.

US12599785B2: Wearable Stereotactic Device, Apr 14

US12599785B2: Wearable Stereotactic Device, Apr 14

Olympus Endoscope System and Endoscopic Ligator Attachment Method Patent US12599385B2

The USPTO granted Patent US12599385B2 to Olympus Medical Systems Corp. for an endoscope system and endoscopic ligator attachment method. The patent covers an endoscope with an insertion section, a coupling thread with a coupling portion and thread portion, and a distal end cover that moves on the outer surface of the insertion section. The patent contains 18 claims and issues from Application No. 18115937, which was filed on March 1, 2023. This patent grant establishes enforceable intellectual property rights for Olympus Medical Systems Corp., granting them exclusive rights to practice the claimed endoscope system invention. Competitors in the medical device sector should monitor this patent when developing similar endoscopic devices to avoid potential infringement. The patent provides 20-year exclusivity from the filing date.

EPA Releases Draft Sixth Contaminant Candidate List Including Microplastics for Public Comment

The EPA and HHS released a draft Sixth Contaminant Candidate List (CCL 6) on April 2, 2026, adding microplastics among other contaminants for public comment through June 5th. The listing is required under the Safe Drinking Water Act every five years but imposes no regulatory requirements. If microplastics are later included in the Unregulated Contaminant Monitoring Rule 6, public water systems would need to sample and report during 2027-2031. California already requires statewide microplastics monitoring under SB 1422.

FDA Form 483 Response Guidance, March 2026 Draft

FDA Form 483 Response Guidance, March 2026 Draft

Congress Returns, Healthcare Hearings, Kennedy Testifies

McDermott+ Consulting published a weekly healthcare preview noting Congress has returned from recess with a full agenda focused on DHS funding and potential reconciliation legislation. HHS Secretary Robert F. Kennedy Jr. is scheduled to testify before three House committees regarding the President's FY 2027 HHS budget priorities. Multiple healthcare-related committee hearings are scheduled, including sessions on chronic disease prevention, healthcare innovation, fraud prevention in state-run programs, and public health legislation.

HRSA 340B Rebate Model RFI Comments Due April 20; Eli Lilly and Novo Nordisk Restrict 340B Pricing

HRSA has extended the deadline for comments on its proposed 340B rebate model pilot program to April 20, 2026. Eli Lilly and Novo Nordisk have implemented policies requiring covered entities to submit dispensing data for all 340B drugs within 45 days of dispense. These changes increase administrative burden and create risk of pricing denials and cash flow disruption for covered entities.

100% Section 232 Tariffs on Patented Drugs, APIs, and Key Materials

The White House issued a presidential proclamation on April 6, 2026, imposing 100% additional Section 232 national security tariffs on patented pharmaceuticals, active pharmaceutical ingredients, and key starting materials. The tariffs affect pharmaceutical manufacturers and U.S. importers, with phased implementation beginning July 31, 2026 for certain companies and September 29, 2026 for others. Generic pharmaceuticals and U.S.-origin products are excluded from these tariffs.

China Pharma Innovators Pursue Global Expansion via Licensing Deals

A&O Shearman published analysis on how Chinese pharmaceutical companies are expanding internationally through out-licensing, partnership, and NewCo deal structures. The article examines China's emergence as a leading pharma innovation hub responsible for 29% of the world's innovative drug pipeline, with regulatory approval times reduced from 663 days in 2017 to 105 days in 2024. Key legal and regulatory angles for these transaction structures are discussed.

Isoxazolo[5,4-H]quinazoline CDK Inhibitor Patent

USPTO granted patent US12600731B2 to Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. for isoxazolo[5,4-H]quinazoline compounds effective as cyclin-dependent kinase (CDK) inhibitors for treating cell proliferation disorders. The patent contains 23 claims and covers pharmaceutical compositions and methods of treating CDK-mediated diseases.

Benzazepine derivative for vasopressin receptor disease treatment

Benzazepine derivative for vasopressin receptor disease treatment

Halozyme US12600959B2 - Modified PH20 Hyaluronidase Polypeptides

USPTO granted Patent US12600959B2 to Halozyme, Inc. covering modified PH20 hyaluronidase polypeptides with enhanced stability and activity. The patent includes 15 claims spanning formulations, compositions, and uses thereof. Filing date was March 5, 2025, with application number 19071345.

Rare Disease Advisory Council Meeting, Indianapolis, April 17th

The Indiana Department of Health announced a public meeting of the Rare Disease Advisory Council scheduled for Friday, April 17, 2026. The meeting will take place in the Yoho Executive Board Room at 2 N. Meridian St., Indianapolis, IN 46204, with livestream access available. The advisory council includes members appointed by the Governor representing physicians, nurses, pharmacists, pharmaceutical representatives, advocacy organizations, research institutes, and ex-officio members from Indiana Medicaid and the DOI Commissioner.

Certified Health Care Professions Commission Public Meeting Notice

The Indiana Department of Health has published a notice of a public meeting of the Certified Health Care Professions Commission scheduled for April 21, 2026, from noon to 3 p.m. at the Indiana Government Center South, Conference Room C in Indianapolis. The meeting will be livestreamed and is open to the public. Commission members include representatives from nurse aide, registered nurse, health facility administrator, and consumer categories.

US12599381B2 - Surgical Stapler with Removable Power Pack

USPTO granted patent US12599381B2 to RevMedica, Inc. covering a surgical stapler with a removable power pack. The power pack contains motors and engagement members for firing fasteners and articulating the device, with sensors to track firing and articulation positions during surgery. The patent includes 19 claims.

Staple Cartridge Comprising Formation Support Features - US12599382B2

The USPTO granted Patent US12599382B2 to Cilag GmbH International for a staple cartridge comprising formation support features. The patent, granted on April 14, 2026, covers a cartridge body including staple formation features with 20 claims. The filing date was January 17, 2025.

Applied Medical Surgical Stapler Actuation Shaft Retention - US12599383B2

The USPTO granted patent US12599383B2 to Applied Medical Resources Corporation for a powered surgical stapler handle with a retention mechanism. The mechanism applies direction-dependent frictional force on an actuation shaft to prevent unintentional movement of drivetrain components. The retention feature includes a featherboard-like configuration with transverse ribs restricting movement in one direction while permitting movement in the opposite direction.

CILAG Surgical Tissue Detection Patent (US12599379B2)

USPTO granted patent US12599379B2 to CILAG GMBH INTERNATIONAL on April 14, 2026. The patent covers devices, systems, and methods for detecting tissue and foreign objects during surgical operations using electrodes and impedance-based detection. The patent application was filed on February 26, 2024.

Handheld Electromechanical Surgical System Patent

USPTO granted Patent US12599378B2 to Covidien LP covering a handheld electromechanical surgical system. The device features an end effector with opposing jaw members, a drive beam, an adapter assembly, and a handle assembly with a power source, motor, force sensor, and motor controller for maintaining constant force during tissue approximation. The patent contains 17 claims and is classified under CPC codes A61B 90/06, A61B 17/068, A61B 17/072, and A61B 2090/064.

Cilag GmbH Surgical Stapler and Staple Cartridge Patent, US12599380B2

USPTO granted patent US12599380B2 to Cilag GmbH International for a surgical stapler and staple cartridge system. The patent covers a retaining pin assembly design and staple cavity configuration where outermost edges align with or extend beyond the pin rod axis. The patent includes 20 claims and was filed on April 5, 2023.

Revolution Ascend CT Security Vulnerability Recall

Health Canada issued a Type II medical device recall for GE Healthcare Japan Corporation's Revolution Ascend CT systems due to a potential security vulnerability in the AW server deployed via Edison Health Link (EHL) based CT smart subscription. Three lots are affected: AS10G2400087YC, AS10G2400056YC, and AS10G2400081YC, all with model/catalogue number 00840682146173. Healthcare providers using these devices should contact the manufacturer for additional information regarding the cybersecurity vulnerability.